Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent
| 대상 질환 | Arthritis, Psoriatic |
|---|---|
| 임상 단계 | 3상 |
| 스폰서 | Janssen Research & Development, LLC |
| 상태 | 진행 중(모집 완료) |
| 참여자 수 | 453 명 |
| 중재(약물) | Guselkumab |
| 시작일 | 2021년 9월 28일 |
| 완료일 | 2024년 10월 28일 |
| 결과 공개일 | 2025년 12월 8일 |
요약
The purpose of this study is to evaluate the efficacy of guselkumab treatment in participants with active psoriatic arthritis (PsA) and inadequate response (IR) and/or intolerance to a prior anti-tumor necrosis factor (TNF) by assessing the reduction in signs and symptoms of PsA.
Percentage of Participants Who Achieved an American College of Rheumatology (ACR) 20 Response at Week 24
| Placebo Followed by Guselkumab 100 mg | 35.9 Percentage of participants |
|---|---|
| Guselkumab 100 mg q8w | 63.0 Percentage of participants |
| Guselkumab 100 mg q4w | 60.9 Percentage of participants |
BENITIONS에서 보기 ClinicalTrials.gov 원문 보기
같은 질환의 다른 임상
- A Study to Assess the Pharmacokinetics, Safety, and Efficacy of Two Doses of Bimekizumab i — UCB Biopharma SRL
- A Study of JNJ-77242113 for the Treatment of Participants With Generalized Pustular Psoria — Janssen Pharmaceutical K.K.
- A Study of Guselkumab and Golimumab Combination Therapy in Participants With Active Psoria — Janssen Research & Development, LLC
- A Study to Evaluate the Efficacy and Safety of Bimekizumab in the Treatment of Subjects Wi — UCB Biopharma SRL
- A Study to Test the Efficacy and Safety of Bimekizumab in the Treatment of Subjects With A — UCB Biopharma SRL
- The Efficacy and Safety of TLL018 in Moderate-to-severe Plaque Psoriasis — Hangzhou Highlightll Pharmaceutical Co., Ltd